FAST NEWS: Innovent Bio’s loss narrows on strong sales growth
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced Wednesday its annual net loss last year narrowed 52.8% year-over-year to 1.03 billion yuan ($143 million), while its non-GAAP net narrowed by an even…
FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Thursday it recorded product revenue of more than 1.6 billion yuan ($2.2 million) in the third quarter, up 45% year-on-year, and also…
RELATED ARTICLES
-
Innovent ditches low-value stake sale after investor outcry
1801.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Innogen Pharma jostles for a slice of the weight-loss market
- PegBio aims to bulk up its finances to deliver weight-loss drugs
